# Intercept Pharmaceuticals clinical trials: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials with Intercept Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Intercept Pharmaceuticals: 22 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/intercept-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 5, 2024 | NCT06488911 | To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate | Intercept Pharmaceuticals | Phase 3 | Terminated | Primary Biliary Cholangitis | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06488911) |
| November 7, 2023 | NCT06121375 | Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to... | Intercept Pharmaceuticals | Phase 2/3 | Terminated | Biliary Atresia | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06121375) |
| December 6, 2022 | NCT05639543 | FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Intercept Pharmaceuticals | Phase 2 | Terminated | Alcohol Associated Hepatitis | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05639543) |
| April 11, 2022 | NCT05321524 | Obeticholic Acid in Pediatric Subjects With Biliary Atresia | Intercept Pharmaceuticals | Phase 2 | Terminated | Biliary Atresia | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05321524) |
| March 24, 2022 | NCT05293938 | A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients | Intercept Pharmaceuticals | Observational | Withdrawn | Primary Biliary Cholangitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05293938) |
| March 23, 2022 | NCT05292872 | Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients | Intercept Pharmaceuticals | Observational | Completed | Primary Biliary Cholangitis | 4,577 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05292872) |
| February 15, 2022 | NCT05239468 | Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | Intercept Pharmaceuticals | Phase 2 | Completed | Primary Biliary Cholangitis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05239468) |
| October 20, 2020 | NCT04594694 | Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC | Intercept Pharmaceuticals | Phase 2 | Terminated | Primary Biliary Cholangitis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04594694) |
| August 16, 2018 | NCT03633227 | Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic... | Intercept Pharmaceuticals | Phase 4 | Terminated | Liver Cirrhosis, Biliary | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03633227) |
| February 20, 2018 | NCT03439254 | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis | Intercept Pharmaceuticals | Phase 3 | Completed | Compensated Cirrhosis, Nonalcoholic Steatohepatitis | 919 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03439254) |
| December 17, 2015 | NCT02633956 | Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) | Intercept Pharmaceuticals | Phase 2 | Completed | Nonalcoholic Steatohepatitis | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02633956) |
| September 14, 2015 | NCT02548351 | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment | Intercept Pharmaceuticals | Phase 3 | Terminated | Non Alcoholic Steatohepatitis (NASH) | 2,477 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02548351) |
| December 4, 2014 | NCT02308111 | Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis | Intercept Pharmaceuticals | Phase 4 | Terminated | Liver Cirrhosis, Biliary | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02308111) |
| June 27, 2014 | NCT02177136 | Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) | Intercept Pharmaceuticals | Phase 2 | Completed | Primary Sclerosing Cholangitis (PSC) | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02177136) |
| September 2, 2013 | NCT01933503 | Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA) | Intercept Pharmaceuticals | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01933503) |
| August 2, 2013 | NCT01914562 | Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA) | Intercept Pharmaceuticals | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01914562) |
| July 22, 2013 | NCT01904539 | Hepatic Impairment Trial of Obeticholic Acid | Intercept Pharmaceuticals | Phase 1 | Completed | Hepatic Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01904539) |
| May 31, 2013 | NCT01865812 | Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis | Intercept Pharmaceuticals | Phase 2 | Completed | Primary Biliary Cirrhosis | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01865812) |
| November 17, 2011 | NCT01473524 | Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis | Intercept Pharmaceuticals | Phase 3 | Completed | Primary Biliary Cirrhosis | 217 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01473524) |
| December 11, 2007 | NCT00570765 | Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) | Intercept Pharmaceuticals | Phase 2 | Completed | Liver Cirrhosis, Biliary | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00570765) |
| October 30, 2007 | NCT00550862 | Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) | Intercept Pharmaceuticals | Phase 2 | Terminated | Liver Cirrhosis, Biliary | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00550862) |
| July 16, 2007 | NCT00501592 | Study of INT-747 in Patients With Diabetes and Presumed NAFLD | Intercept Pharmaceuticals | Phase 2 | Completed | Diabetes Mellitus, Type II, Fatty Liver | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00501592) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Terminated | 9 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Liver Cirrhosis, Biliary | 11 |
| Fibrosis | 5 |
| Non-alcoholic Fatty Liver Disease | 4 |
| Biliary Atresia | 2 |
| Hepatitis, Alcoholic | 1 |
| Hepatitis | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Fatty Liver | 1 |
| Metabolic Diseases | 1 |
| Diabetes Mellitus | 1 |
| Cholangitis, Sclerosing | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Korean restaurants in the United States](https://specstream.ai/data/businesses/korean-restaurants/united-states)
- [Medical schools in the United States](https://specstream.ai/data/businesses/medical-schools/united-states)
- [Optometrists in the United States](https://specstream.ai/data/businesses/optometrists/united-states)
- [Plasterers in the United States](https://specstream.ai/data/businesses/plasterers/united-states)
